Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: GR who wrote (557)	10/19/1998 2:25:00 AM
From: DavidCG	Read Replies (1) \| Respond to of 1255

So you are saying... on the first round of hype it spiked to $3.50. Boy, that sure would be disappointing if CORX spiked up from .90 to $3.50 again on this hype. Wouldn't it? You just have to hate those potential 400% returns! <G> -DavidCG

To: GR who wrote (557)	10/19/1998 9:10:00 AM
From: Michael Olin	Read Replies (2) \| Respond to of 1255

The compounds (Ampakines) were mentioned in an NBC Nightly News story about memory loss at the end of 1996 and a cover story in a West coast newspaper (I think the LA Times) the following morning. The stock spiked from $3 and change to almost $7. Either someone at NBC is keeping an eye on Cortex (back burner sort of stuff, waiting for some significant news) or they just happen to be doing the same story every couple of years. I think that the May 1998 spike was related to promising schizophrenia results, not memory loss. Today should be interesting. Considering that I've been holding this one since the pre-hype $7 days, I doubt that anything other than an announced partnership or definitive results from the NIH trials will do much for my position. Then again, I knew that buy-and-hold would only make me money on CORX if they got a compound to market when I bought the stock. Good luck to all the traders and the handful of LONG-suffering investors like me out there. -Michael